Advertisement

Topics

22nd Century Conducts Three Short-Term Studies in Support of the Company’s MRTP Application to the FDA

09:45 EDT 20 Jun 2018 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Study details available at www.clinicaltrials.gov 22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is a leader in tobacco harm reduction and Very Low Nicotine Content tobacco, announced tha...

Other Sources for this Article

22nd Century Group
James Vail, Director of Communications
716-270-1523
jvail@xxiicentury.com

NEXT ARTICLE

More From BioPortfolio on "22nd Century Conducts Three Short-Term Studies in Support of the Company’s MRTP Application to the FDA"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...